Viking Therapeutics: Strategic Growth and Strong Buy Rating Amidst Advancements in Obesity Drug Pipeline
Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...
ETF Daily News18d
Viking Therapeutics, Inc. (NASDAQ:VKTX) CEO Brian Lian Sells 194,490 Shares of Stock
Viking Therapeutics, Inc. has a 1 year low of $18.14 and a 1 year high of $99.41. The firm has a market capitalization of $4.74 billion, a PE ratio of -45.73 and a beta of 0.95. Get Viking ...
Promising Clinical Developments and Strategic Initiatives Drive Buy Rating for Viking Therapeutics
BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...
Yardbarker5h
How insider's theory on Jaguars' messy Liam Coen hire relates to Vikings DC Brian Flores' lawsuit against the NFL
The Minnesota Vikings are incredibly lucky to have defensive coordinator Brian Flores on staff for now — and likely in the future as well. However, Flores deserves to have a head-coaching job.
bovnews3d
Why Did Viking Therapeutics Inc (VKTX) Stock Plunge -15.46% Last Week?
Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $32.87 which represents a slight increase of $0.22 or 0.67% from the prior close of $32.65. The stock opened at $32.87 and ...